The company will evaluate Combretastatin A4P (CA4P), in combination with concurrent chemo-radiotherapy, a widely accepted standard in the US for the treatment of unresectable stage IIIa/IIIb non small cell lung cancer (NSCLC).
The phase II clinical trial will initially enroll approximately 12 patients to assess the tolerability of the protocol and to establish the recommended dose of intravenously administered CA4P.
In other ongoing clinical trials, CA4P has been paired with chemotherapy or radiation therapy with no observed side effects beyond those typically experienced with either treatment.
The trial will then proceed to compare approximately 66 patients who will be split into an investigational group and an active control group.
“We believe this phase II clinical trial to be a key stepping stone in the path towards potential commercialization of CA4P for the treatment of NSCLC,” commented Frederick Driscoll, president and CEO of Oxigene.